8-K: VolitionRx Waives Investor Rights for ATM Sales

VolitionRx Limited has entered into a waiver and consent agreement with Lind Global Asset Management XII LLC, allowing for sales under its ATM agreement to exceed previous limits without triggering default remedies or anti-dilution adjustments.

Summary

• VolitionRx Limited (the Company) and Lind Global Asset Management XII LLC (Lind) have entered into a Waiver and Consent agreement dated September 2, 2026.
• This agreement allows the Company to sell shares under its At-the-Market (ATM) agreement in excess of the previously agreed $10 million annual limit without these sales being considered 'Prohibited Transactions'.
• Lind has waived its rights and remedies related to 'Prohibited Transactions' and 'Events of Default' that could arise from these excess ATM sales.
• This waiver also includes the forfeiture of rights to declare amounts due, demand immediate payment, accelerate obligations, or foreclose on collateral due to such sales.
• Furthermore, Lind has waived any adjustments to the Conversion Price of the Notes and the Exercise Price of the Warrants for sales occurring after August 28, 2026.
• The Conversion Price for the Notes is adjusted to $0.44 and the Exercise Price for the Warrants to $0.572 due to prior excess ATM sales.
• The Company's obligation to direct 20% of proceeds from ATM sales exceeding exempted securities towards repayment of the Notes remains, unless waived in writing by Lind.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the company waiving certain rights and potentially diluting existing security holders, despite the immediate operational flexibility it provides.

Positives

• Provides immediate operational flexibility for VolitionRx to raise capital through its ATM program without immediate default concerns.
• Secures continued consent from a key investor (Lind) for ongoing capital raising activities.
• Clarifies the conversion and exercise prices for existing notes and warrants based on past ATM sales.

Negatives

• The company has waived significant investor protections, including remedies for default and anti-dilution adjustments.
• Potential for significant dilution to existing shareholders as the $10 million annual cap on ATM sales has been removed.
• The waiver of remedies by Lind could be seen as a sign of financial distress or a need for immediate capital.

Risks

• Increased dilution for existing shareholders due to the removal of the $10 million annual limit on ATM sales.
• Potential for further financial strain if the company continues to rely heavily on ATM sales without corresponding revenue growth.
• The waiver of remedies by Lind could embolden other creditors or investors to seek similar concessions or take adverse actions.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. However, the waiver facilitates ongoing capital raising activities through the ATM program, suggesting a continued need for funding.

Management Comments

• The company may sell up to $10 million under its ATM Agreement during any calendar year as Permitted ATM Sales.
• Lind consented to any and all sales under the ATM Agreement, including amounts in excess of $10 million during any calendar year, as constituting Permitted ATM Sales and not Prohibited Transactions.
• Lind also waived the remedies available under the Purchase Agreement and Notes for Prohibited Transactions and Events of Default triggered by ATM sales.

Industry Context

StockSavvy.ai notes that the removal of ATM sales caps and the waiver of investor remedies are often indicative of companies facing significant cash burn or requiring substantial funding for operations or development, a common scenario in early-stage or development-heavy industries like biotechnology.

Comparison to Industry Standards

• In the biotechnology sector, companies frequently utilize ATM facilities for capital raises. However, agreements typically include covenants and protections for investors, such as limits on sales volume and anti-dilution provisions, to mitigate shareholder dilution.
• The waiver of these standard protections by Lind, as detailed in this filing, deviates from typical investor agreements in the sector, suggesting a unique or potentially strained relationship between VolitionRx and its investor.
• Competitors in the biotech space often secure funding through a mix of equity offerings, debt financing, and strategic partnerships, with terms negotiated to balance the company's need for capital against investor risk and return expectations.

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership and earnings per share due to the removal of ATM sales limits. The waiver of anti-dilution protection also negatively impacts the value of their holdings.
• Creditors (other than Lind): May be concerned about the company's financial health and its ability to repay other debts if it relies heavily on dilutive capital raises.
• Lind Global Asset Management XII LLC: Benefits from the ability to continue sales under the ATM agreement without triggering default remedies, while also having its conversion and exercise prices adjusted.

Next Steps

• VolitionRx can now proceed with ATM sales exceeding the $10 million annual limit without triggering default provisions or anti-dilution adjustments for Lind.
• The company must continue to adhere to the obligation of directing 20% of proceeds from certain ATM sales towards note repayment, unless otherwise waived.

Key Dates

Recommendation

The waiver of critical investor protections and the removal of ATM sales limits suggest a company under financial pressure, leading to significant potential dilution for existing shareholders. This action indicates a worsening financial position and a need for capital that outweighs the protection of current equity value.

Keywords

ATM sales, Waiver and Consent, Convertible Promissory Note, Stock Purchase Warrant, Capital Raise, Dilution, Securities Purchase Agreement, Event of Default